HorizonStudio
HorizonStudio Raises $100M Growth to Transform Biotech
Quick Facts
HorizonStudio Raises $100M Growth in Latest Funding Round
HorizonStudio has successfully closed a $100M Growth funding round, marking a significant milestone in the company's growth trajectory. The round was led by Lightspeed Venture Partners, with participation from Greylock Partners.
Company Overview
Founded in 2023 and headquartered in Washington, DC, HorizonStudio has established itself in the Biotech space. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses
With a current valuation of $10B, the company has demonstrated strong market traction and investor confidence.
Investment Details
- Amount Raised: $100M Growth
- Valuation: $10B
- Lead Investor: Lightspeed Venture Partners
Future Outlook
As HorizonStudio moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.
Key Investors
About the Author
Related Company Reports
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza